Distribution of baseline patient characteristics in the 5 IPD trials of IL-2 alone versus control (no treatment)
| Baseline characteristics at diagnosis* . | Blaise et al20 . | ALFA 980121 . | CALGB 972022 . | CALGB 1980823 . | CCG-296124 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment (n) . | IL-2 (40) . | Control (38) . | IL-2 (77) . | Control (84) . | IL-2 (81) . | Control (82) . | IL-2 (107) . | Control (107) . | IL-2 (144) . | Control (145) . |
| Mean age, y (SD) | 38.9 (12.1) | 41.2 (11.4) | 60.6 (5.3) | 59.6 (5.3) | 69.3 (5.6) | 69.5 (5.9) | 43.3 (10.6) | 42.9 (10.7) | 8.0 (5.4) | 8.4 (5.7) |
| Sex, n (M/F) | 22/18 | 17/21 | 40/37 | 43/41 | 41/40 | 52/30 | 50/57 | 62/45 | 89/55 | 67/78 |
| ECOG performance status, n | NA | NA | NA | NA | ||||||
| 0 | 23 | 25 | 30 | 29 | 44 | 44 | ||||
| 1 | 40 | 49 | 40 | 34 | 52 | 48 | ||||
| 2 | 10 | 6 | 8 | 14 | 6 | 8 | ||||
| 3 | 3 | 0 | 2 | 1 | 2 | 2 | ||||
| Karyotype, n† | ||||||||||
| Favorable | 8 | 9 | 4 | 14 | 13 | 19 | 32 | 33 | 26 | 26 |
| Intermediate | 17 | 17 | 56 | 53 | 38 | 39 | 52 | 52 | 55 | 44 |
| Unfavorable | 0 | 2 | 7 | 9 | 10 | 7 | 7 | 3 | 1 | 2 |
| AML subtype, n‡ | ||||||||||
| M0-M5-M6-M7 | 9 | 7 | 25 | 24 | 17 | 18 | 19 | 15 | 44 | 46 |
| M1-M2-M4 | 30 | 24 | 52 | 60 | 60 | 60 | 81 | 84 | 99 | 94 |
| Months from CR, mean (SD) | 3.5 (0.9) | 3.5 (1.1) | 4.3 (0.9) | 4.2 (1.7) | 2.2 (0.9) | 2.3 (1.0) | 5.1 (1.4) | 5.2 (1.7) | 4.2 (1.3) | 4.4 (1.7) |
| Baseline characteristics at diagnosis* . | Blaise et al20 . | ALFA 980121 . | CALGB 972022 . | CALGB 1980823 . | CCG-296124 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment (n) . | IL-2 (40) . | Control (38) . | IL-2 (77) . | Control (84) . | IL-2 (81) . | Control (82) . | IL-2 (107) . | Control (107) . | IL-2 (144) . | Control (145) . |
| Mean age, y (SD) | 38.9 (12.1) | 41.2 (11.4) | 60.6 (5.3) | 59.6 (5.3) | 69.3 (5.6) | 69.5 (5.9) | 43.3 (10.6) | 42.9 (10.7) | 8.0 (5.4) | 8.4 (5.7) |
| Sex, n (M/F) | 22/18 | 17/21 | 40/37 | 43/41 | 41/40 | 52/30 | 50/57 | 62/45 | 89/55 | 67/78 |
| ECOG performance status, n | NA | NA | NA | NA | ||||||
| 0 | 23 | 25 | 30 | 29 | 44 | 44 | ||||
| 1 | 40 | 49 | 40 | 34 | 52 | 48 | ||||
| 2 | 10 | 6 | 8 | 14 | 6 | 8 | ||||
| 3 | 3 | 0 | 2 | 1 | 2 | 2 | ||||
| Karyotype, n† | ||||||||||
| Favorable | 8 | 9 | 4 | 14 | 13 | 19 | 32 | 33 | 26 | 26 |
| Intermediate | 17 | 17 | 56 | 53 | 38 | 39 | 52 | 52 | 55 | 44 |
| Unfavorable | 0 | 2 | 7 | 9 | 10 | 7 | 7 | 3 | 1 | 2 |
| AML subtype, n‡ | ||||||||||
| M0-M5-M6-M7 | 9 | 7 | 25 | 24 | 17 | 18 | 19 | 15 | 44 | 46 |
| M1-M2-M4 | 30 | 24 | 52 | 60 | 60 | 60 | 81 | 84 | 99 | 94 |
| Months from CR, mean (SD) | 3.5 (0.9) | 3.5 (1.1) | 4.3 (0.9) | 4.2 (1.7) | 2.2 (0.9) | 2.3 (1.0) | 5.1 (1.4) | 5.2 (1.7) | 4.2 (1.3) | 4.4 (1.7) |
IPD indicates individual patient data; and NA, data not available.
Based on intention-to-treat.
Favorable, intermediate, and unfavorable karyotypes were defined as in each trial.20,,,–24,28
Seven M3 patients entered in the trial by Blaise et al20 have been excluded from this grouping of histological subtypes.